相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J. DeAngelo et al.
BLOOD (2006)
A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model
Hiroaki Ohno et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis
J Condeelis et al.
CELL (2006)
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518
JJ Clark et al.
BLOOD (2004)
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
LJ Murray et al.
CLINICAL & EXPERIMENTAL METASTASIS (2003)
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
LM Kelly et al.
CANCER CELL (2002)
Class III receptor tyrosine kinases: Role in leukaemogenesis
JT Reilly
BRITISH JOURNAL OF HAEMATOLOGY (2002)
分享论文
